Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Adv Med Sci. 2019 Mar;64(1):195-201. doi: 10.1016/j.advms.2018.08.017. Epub 2019 Feb 13.
The role of insulin-like growth factor-binding protein-7 (IGFBP-7) in atherosclerosis is still not well-known. The objective of this study was to find out the following: 1) whether IGFBP-7 may act as a biomarker of coronary artery disease (CAD) occurrence and extent; 2) whether IGFBP-7 is potentially related to the classical and new markers of cardiovascular risk (carotid intima-media thickness - cIMT); 3) whether IGFBP-7 may be a marker of mortality in the group of patients with myocardial infarction (MI).
MATERIALS/METHODS: The study group consisted of 212 patients with MI and 75 patients with stable CAD, the control group included 100 healthy volunteers. IGFBP-7 serum concentration was measured.
IGFBP-7 value was considerably higher in the study group (MI and CAD patients - 35.1 ng/ml (P = 0.000001) and 32.7ng/ml (P = 0.0001), respectively), than in the controls - 25.2ng/ml. No statistically significant differences between IGFBP-7 concentrations in the MI and CAD group were found. No relationship between IGFBP-7 and the coronary lesions advancement in the study group was observed. No changes in IGFBP-7 concentration in the MI patients during hospitalization were observed. In the group of MI patients who died during follow-up, a considerably higher cIMT values were found whereas no statistically significant difference was observed in relation to IGFBP-7 (34.6 vs. 35.2 ng/ml).
IGFBP-7 is a good biomarker of CAD occurrence but not of its advancement. We demonstrated the existence of the relation between higher IGFBP-7 concentration and the selected classical risk factors of cardiovascular events as well as cIMT values. IGFBP-7 cannot serve as a marker of acute ischemia. Also, IGFBP-7 was not confirmed as a predictor of mortality in the MI patients.
胰岛素样生长因子结合蛋白-7（IGFBP-7）在动脉粥样硬化中的作用尚不清楚。本研究旨在探讨以下问题：1）IGFBP-7 是否可以作为冠心病（CAD）发生和严重程度的生物标志物；2）IGFBP-7 是否与心血管风险的经典和新型标志物（颈动脉内膜中层厚度 - cIMT）有关；3）IGFBP-7 是否可作为心肌梗死（MI）患者死亡的标志物。
材料/方法：研究组包括 212 例 MI 患者和 75 例稳定型 CAD 患者，对照组包括 100 名健康志愿者。测量 IGFBP-7 血清浓度。
研究组（MI 和 CAD 患者）IGFBP-7 值分别为 35.1ng/ml（P=0.000001）和 32.7ng/ml（P=0.0001），显著高于对照组（25.2ng/ml）。MI 和 CAD 组之间 IGFBP-7 浓度无统计学差异。在研究组中，未观察到 IGFBP-7 与冠状动脉病变进展之间的关系。MI 患者住院期间 IGFBP-7 浓度无变化。在随访期间死亡的 MI 患者中，cIMT 值明显较高，但 IGFBP-7 无统计学差异（34.6 与 35.2ng/ml）。
IGFBP-7 是 CAD 发生的良好生物标志物，但不是其进展的标志物。我们证明了 IGFBP-7 浓度与心血管事件的某些经典危险因素以及 cIMT 值之间存在相关性。IGFBP-7 不能作为急性缺血的标志物。此外，IGFBP-7 并未被证实是 MI 患者死亡的预测因子。
